With the three programs – in the areas of oncology, rare disease, and respiratory – the contract research organization (CRO) expects to recruit nearly 3,000 patients at approximately 270 investigator sites across the US.
Troy McCall, Cromsource, chief operating officer, told Outsourcing-Pharma.com that that company’s board has approved significant investments in its capabilities and infrastructure in the US over the last year.
The company has opened a new office in Raleigh, NC, and relocated its US Headquarters to Waltham, MA, “and in doing so tripled the size of that office,” added McCall.
The CRO hired approximately 60 new employees in the US to support growth in the company’s core areas of oncology, respiratory, ophthalmology, medical devices, and rare diseases.
“Over the next five years, Cromsource will continue to grow organically – primarily in our core areas – and may pursue certain acquisitions that allow us to further advance our mission of becoming the CRO partner of choice for our clients,” McCall said.